A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) identifier:
NCT03992131 (

Study Contact Information:

Clovis Oncology Clinical Trial Navigation, phone: 1-855-262-3040 or email    

About the Study

This study will look at how safe, effective and tolerable the oral PARP inhibitor Rucaparib is when used in combination with other anticancer agents in patients with a solid tumor. Note: This study has completed enrollment. 

Type of Study

This is an open-label study, with two treatment arms. 

What the Study Entails

Participants will be assigned to one of two groups:

Participants in both groups will be followed for up to two years. 

Study Sites


This Study is Open To:

Note: This study has completed enrollment. 

This Study is Not Open To:

For Phase 1, the following exclusions apply:

For Phase 2, the following exclusions apply: 


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.